Cost-utility analysis of methylphenidate treatment for children and adolescents with ADHD in Brazil
| Autor: | Carlos R. Maia, Steffan F. Stella, Flavia Wagner, Thiago G. Pianca, Fernanda V. Krieger, Luciane N. Cruz, Guilherme V. Polanczyk, Luís A. Rohde, Carísi A. Polanczyk |
|---|---|
| Jazyk: | English<br />Portuguese |
| Rok vydání: | 2015 |
| Předmět: | |
| Zdroj: | Brazilian Journal of Psychiatry, Iss 0, Pp 0-0 (2015) |
| Druh dokumentu: | article |
| ISSN: | 1809-452X 1516-4446 |
| DOI: | 10.1590/1516-4446-2014-1516 |
| Popis: | Objective:To perform a cost-utility analysis on the treatment of attention deficit hyperactivity disorder (ADHD) with methylphenidate immediate-release (MPH-IR) in children and adolescents from Brazil.Method:A Markov model was constructed to compare MPH-IR vs. no treatment. A 24-week naturalistic study was conducted to collect transition probabilities and utility data. Effectiveness was expressed as quality-adjusted life-years (QALY), and costs reported in 2014 international dollars (I$). The perspective was the Brazilian Unified Health System as payer, and the time horizon was 6 years.Results:Of 171 patients, 73 provided information at baseline, and 56 at week 24. Considering the MPH-IR monthly cost of I$ 38, the incremental cost-effectiveness ratio (ICER) of treatment was I$ 9,103/QALY for children and I$ 11,883/QALY for adolescents. In two-way sensitivity analysis, considering one Gross National Product per capita (I$ 11,530) as willingness-to-pay, a cost of no-treatment lower than I$ 45/month would render MPH-IR a cost-saving strategy.Discussion:MPH-IR treatment of children and adolescents is cost-effective for ADHD patients from the Brazilian public health system perspective. Both patients and the healthcare system might benefit from such a strategy.Trial registration number:NCT01705613. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|